Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36122315

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 Jan 10
First author
Drilon A

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Jan 10;41(2):410-412. doi: 10.1200/JCO.22.01644.
    note
    Source null
    related pmid
    36122320
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Dec;19(12):747. doi: 10.1038/s41571-022-00694-2.
    note
    Source null
    related pmid
    36207414
    relationship
    Comment in
  3. citation
    Transl Lung Cancer Res. 2023 Jul 31;12(7):1655-1657. doi: 10.21037/tlcr-23-202.
    note
    Source null
    related pmid
    37577312
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2023 Nov 1;41(31):4941. doi: 10.1200/JCO.23.01849.
    note
    Source null
    related pmid
    37703508
    relationship
    Erratum in

Authors and identifiers

  1. name
    Drilon A
    type
    Author
  2. name
    Subbiah V
    type
    Author
  3. name
    Gautschi O
    type
    Author
  4. name
    Tomasini P
    type
    Author
  5. name
    de Braud F
    type
    Author
  6. name
    Solomon BJ
    type
    Author
  7. name
    Shao-Weng Tan D
    type
    Author
  8. name
    Alonso G
    type
    Author
  9. name
    Wolf J
    type
    Author
  10. name
    Park K
    type
    Author
  11. name
    Goto K
    type
    Author
  12. name
    Soldatenkova V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Drilon A
    type
    Author
  2. name
    Subbiah V
    type
    Author
  3. name
    Gautschi O
    type
    Author
  4. name
    Tomasini P
    type
    Author
  5. name
    de Braud F
    type
    Author
  6. name
    Solomon BJ
    type
    Author
  7. name
    Shao-Weng Tan D
    type
    Author
  8. name
    Alonso G
    type
    Author
  9. name
    Wolf J
    type
    Author
  10. name
    Park K
    type
    Author
  11. name
    Goto K
    type
    Author
  12. name
    Soldatenkova V
    type
    Author
bibliography ids
  1. nci-bib-713801c4337b1d384f64900a
book metadata
content sha256
95a47d723ff28fe986e452fd40141a6a31dcdd6a9f09d02f225365291b93c15a
document type
citation
dois
  1. 10.1200/JCO.22.00393
electronic publication date
display
2022 Sep 19
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36122315
immutable id
pubmed:36122315@95a47d723ff28fe986e452fd40141a6a31dcdd6a9f09d02f225365291b93c15a
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
2
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
385-394
volume
41
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Jan 10;41(2):410-412. doi: 10.1200/JCO.22.01644.
    note
    Source null
    related pmid
    36122320
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Dec;19(12):747. doi: 10.1038/s41571-022-00694-2.
    note
    Source null
    related pmid
    36207414
    relationship
    Comment in
  3. citation
    Transl Lung Cancer Res. 2023 Jul 31;12(7):1655-1657. doi: 10.21037/tlcr-23-202.
    note
    Source null
    related pmid
    37577312
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2023 Nov 1;41(31):4941. doi: 10.1200/JCO.23.01849.
    note
    Source null
    related pmid
    37703508
    relationship
    Erratum in
outcomes validated
false
pmid
36122315
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
37b989c1f3cce982a7347da09068b47f3723b6c97e747e4862e98ac95f7a1820
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 Jan 10
precision
day
year
2023
publication types
  1. Clinical Trial, Phase II
  2. Clinical Trial, Phase I
  3. Journal Article
  4. Research Support, N.I.H., Extramural
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36122315/
title
Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.

Preserved source evidence · Not medical advice